This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
== Interactions == Mianserin may enhance the sedative effects of drugs such as alcohol, anxiolytics, hypnotics, or antipsychotics when co-administered. It may decrease the efficacy of antiepileptic medications. Carbamazepine and phenobarbital will cause the body to metabolize mianserin faster and may reduce its effects. There is a risk of dangerously low blood pressure if people take mianserin along with diazoxide, hydralazine, or nitroprusside. Mianserin can make antihistamines and antimuscarinics have stronger effects. Mianserin should not be taken with apraclonidine, brimonidine, sibutramine, or the combination drug of artemether with lumefantrine.
== Medical uses == Polatuzumab vedotin is indicated in combination with bendamustine and a rituximab product for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adults with previously untreated diffuse large B-cell lymphoma (DLBCL).
== Definition == The chirality of a molecule is based on the molecular symmetry of its conformations. A conformation of a molecule is chiral if and only if it belongs to the Cn, Dn, T, O, or I point groups (the chiral point groups). However, whether the molecule itself is considered to be chiral depends on whether its chiral conformations are persistent isomers that could be isolated as separated enantiomers, at least in principle, or the enantiomeric conformers rapidly interconvert at a given temperature and timescale through low-energy conformational changes (rendering the molecule achiral). For example, despite having chiral gauche conformers that belong to the C2 point group, butane is considered achiral at room temperature because rotation about the central C–C bond rapidly interconverts the enantiomers (3.4 kcal/mol barrier). Similarly, cis-1,2-dichlorocyclohexane consists of chair conformers that are nonidentical mirror images, but the two can interconvert via the cyclohexane chair flip (~10 kcal/mol barrier). As another example, amines with three distinct substituents (R1R2R3N:) are also regarded as achiral molecules because their enantiomeric pyramidal conformers rapidly undergo pyramidal inversion. However, if the temperature in question is low enough, the process that interconverts the enantiomeric chiral conformations becomes slow compared to a given timescale. The molecule would then be considered to be chiral at that temperature.
=== Derivation and other names === Several names are sometimes used synonymously although some of these have other meanings that are not necessarily interchangeable: amphoteric element, boundary element, half-way element, near metal, meta-metal, semiconductor, semimetal and submetal. "Amphoteric element" is sometimes used more broadly to include transition metals capable of forming oxyanions, such as chromium and manganese. "Meta-metal" is sometimes used instead to refer to certain metals (Be, Zn, Cd, Hg, In, Tl, β-Sn, Pb) located just to the left of the metalloids on standard periodic tables. These metals tend to have distorted crystalline structures, electrical conductivity values at the lower end of those of metals, and amphoteric (weakly basic) oxides. The names amphoteric element and semiconductor are problematic as some elements referred to as metalloids do not show marked amphoteric behaviour (bismuth, for example) or semiconductivity (polonium) in their most stable forms.
Sources: en.wikipedia.org
== Early life == Cave grew up in New Orleans, Louisiana. She studied at Lusher Charter High School. She returned to her alma mater in 2017 to deliver the commencement speech. Cave did ballet, track, and cheerleading before dropping those programs to pursue research in nanotechnology. Cave attributes her early interest in engineering to the Project Lead the Way (PLTW) Program, for which she later became a national ambassador. In 2014 she won $10,000 in New Orleans Entrepreneur Week's Trust Your Crazy Ideas Challenge hosted by NFL Quarterback Drew Brees.
In 2010, the last of the prisons were turned over to the Iraqi government to run. An Associated Press article said Despite Abu Ghriab- or perhaps because of reforms in its wake- prisoners have more recently said they receive far better treatment in American custody than in Iraqi jails. In September 2010 Amnesty International warned in a report titled New Order, Same Abuses; Unlawful Detentions and Torture in Iraq that up to 30,000 prisoners, including many veterans of the US detention system, remain detained without rights in Iraq and are frequently tortured or abused. Furthermore, it describes a detention system that has not evolved since Saddam Hussein's regime, in which human rights abuses were endemic with arbitrary arrests and secret detention common and a lack of accountability throughout the security forces. Amnesty's Middle East and North Africa director, Malcolm Smart went on to say that "Iraq's security forces have been responsible for systematically violating detainees' rights and they have been permitted. US authorities, whose own record on detainees' rights has been so poor, have now handed over thousands of people detained by US forces to face this catalogue of illegality, violence and abuse, abdicating any responsibility for their human rights." On October 22, 2010 nearly 400,000 secret United States army field reports and war logs, detailing torture, summary executions and war crimes, were passed on to the British paper, the Guardian and several other international media organisations through the whistleblowing website WikiLeaks.
Conservation strategies include the maintenance of: 1) refuge plants and reservoir hosts to preserve the EcM fungal community after harvesting; 2) mature trees to provide seedlings with a diverse array of EcM fungi; and 3) old-growth stands that have diverse macro- and microhabitats and support varied EcM fungal communities. Preservation of natural forest floor constituents and retention of woody debris and substrates may also be important. In one study concerning Douglas-fir seedlings, removal of forest floor debris and soil compaction decreased EcM fungal diversity and abundance by 60%. Removal of pinegrass similarly reduced the diversity and richness of EcM fungi. Some strategies, such as prescribed burns, have different effects on different types of EcM communities, ranging from negative to neutral or positive. Large ex situ culture collections of fungi, including ectomycorrhizal fungi, are maintained throughout the world as insurance against genetic loss. However, these collections are incomplete.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.